Postoperative Chemotherapy May Not Be Necessary for Patients With ypN0-Category After Neoadjuvant Chemoradiotherapy of Rectal Cancer
Authors:
- Rainer FietkauRFRainer Fietkau
- Malte BartenMBMalte Barten
- Gunther KlautkeGKGunther Klautke
- Ernst KlarEKErnst Klar
- Kaja LudwigKLKaja Ludwig
- Hartmut ThomasHTHartmut Thomas
- Wolfgang BrinckmannWBWolfgang Brinckmann
- Andreas FriedrichAFAndreas Friedrich
- Friedrich PrallFPFriedrich Prall
- Gernot HartungGHGernot Hartung
- Ute KüchenmeisterUKUte Küchenmeister
- Gunther KundtGKGunther Kundt
- 1 September 2006
- journal article
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 49 (9) , 1284-1292
Abstract
After neoadjuvant radiochemotherapy and surgery, there is no general agreement about whether postoperative chemotherapy is necessary. With the help of clinical and pathohistologic data, prognostic factors were determined as a basis for the decision to spare a patient additional chemotherapy or to urgently recommend it. Ninety-five patients treated with neoadjuvant 5-fluorouracil-based radiochemotherapy (November 4, 1997 and June 15, 2004) without distant metastases and an R0 (microscopically complete) resection were evaluated. Adjuvant chemotherapy (5-fluorouracil or 5-fluorouracil/folinic acid) was given to 65 of 95 patients (68.4 percent). The disease-free survival rate after 36 months was chosen as the target parameter (median follow-up, 36 months). The five-year survival rate for all patients was 80.3 ± 5.6 percent; the five-year disease-free survival was 78.1 ± 5.1 percent; the five-year local control rate was 94.2 ± 5.1 percent. In the univariate and multivariate analysis of the disease-free survival, the pathohistologic lymph node status after radiochemotherapy (ypN) was the only significant prognostic parameter. Disease-free survival (36 months) for patients without lymph node metastases (ypN0) was excellent, independent of whether they had received postoperative chemotherapy (n = 43; 87.5 ± 6.0 percent) or not (n = 29; 87.7 ± 6.7 percent). Patients with ypN2 status have, despite chemotherapy, a poor disease-free survival at 30 ± 17.6 percent after 36 months. These retrospective data suggest that, for some patients, postoperative chemotherapy can be spared. For patients with ypN2 status, an intensification of the postoperative chemotherapy should be considered. Further evaluation in prospective studies is urgently recommended.Keywords
This publication has 34 references indexed in Scilit:
- Enhanced Tumorocidal Effect of Chemotherapy With Preoperative Radiotherapy for Rectal Cancer: Preliminary Results—EORTC 22921Journal of Clinical Oncology, 2005
- Phase I Trial of Capecitabine and Weekly Irinotecan in Combination With Radiotherapy for Neoadjuvant Therapy of Rectal CancerJournal of Clinical Oncology, 2005
- Complete Pathologic Response Following Preoperative Chemoradiation Therapy for Middle to Lower Rectal Cancer Is Not a Prognostic Factor for a Better OutcomeDiseases of the Colon & Rectum, 2004
- Preoperative versus Postoperative Chemoradiotherapy for Rectal CancerNew England Journal of Medicine, 2004
- Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal CancerNew England Journal of Medicine, 2001
- Preoperative chemoradiotherapy and radical surgery for locally advanced distal rectal adenocarcinomaDiseases of the Colon & Rectum, 2001
- Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2001
- Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancersInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000
- Preoperative chemoradiation with cisplatin and 5-fluorouracil for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, sphincter preservationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1999
- Improved Survival with Preoperative Radiotherapy in Resectable Rectal CancerNew England Journal of Medicine, 1997